IPSC (Century Therapeutics) Asset Impairment Charge: $0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IPSC Century Therapeutics Inc IPSC
46 GF Score
Price $2.11
GF Value $40.06
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Century Therapeutics Asset Impairment Charge?

Century Therapeutics IPSC +0.96% 46 Asset Impairment Charge is $0.0 Mil as of Jun. 2026. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $40.06 (Possible Value Trap). The stock has 3 warning signs investors should review.

Century Therapeutics's Asset Impairment Charge for the three months ended in Jun. 2026 was $0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was $0.0 Mil.

Century Therapeutics Asset Impairment Charge Related Terms

Century Therapeutics Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Century Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Century Therapeutics Asset Impairment Charge Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial 0.00 0.00 16.37 4.33 6.76

Century Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IPSC
46GF Score
Century Therapeutics Inc IPSC
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Century Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

What does a Asset Impairment Charge of $0.0 Mil mean?
Century Therapeutics (IPSC) has a Asset Impairment Charge of $0.0 Mil as of Jun. 2026.
Is Century Therapeutics' Asset Impairment Charge too high?
Century Therapeutics' current Asset Impairment Charge is $0.0 Mil. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' Asset Impairment Charge compare to UPB and ZNTL?
Century Therapeutics' Asset Impairment Charge of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Century Therapeutics's current Asset Impairment Charge is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $40.06, compared to a current price of $2.11 — trading 94.7% below its estimated fair value. The current Asset Impairment Charge is $0.0 Mil. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current Asset Impairment Charge is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Century Therapeutics (IPSC) Overvalued in 2026?

Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued. The current stock price of $2.11 is trading 94.7% below its estimated GF Value™ of $40.06. GuruFocus considers Century Therapeutics to be Possible Value Trap.

Key valuation signals for IPSC:

  • Asset Impairment Charge: $0.0 Mil
  • GF Value™: $40.06 vs. price of $2.11 (94.7% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Century Therapeutics Business Description

Address 25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score

Get the complete analysis for IPSC

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.11
Price
$40.06
GF Value